Stage
Commercial
Modalities
Bispecific antibodyAntibody-drug conjugate (ADC)

EcoR1 Capital General Information

Investment firm that made a $50M private placement in Zymeworks, gaining rights to nominate board member. Primary investment focus on biotechnology companies.

Contact Information

Website
Primary Industry
Investors
Corporate Office

Drug Pipeline

No pipeline data available

For full access to EcoR1 Capital's pipeline data

Book a demo

Key Partnerships

Zymeworks

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

EcoR1 Capital Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view EcoR1 Capital's complete valuation and funding history, request access »